Supplemental Reading for Chapter 1 Basic Principles of Clinical ...

References for Chapter 9
The Renin-Angiotensin Axis
Angiotensin-Converting Enzyme Inhibitors
and Angiotensin Receptor Blockers
Domenic A. Sica, MD
Todd W. B. Gehr, MD
William H. Frishman, MD
1. The Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure. Hypertension
42:1206, 2003.
2 Brunner HR, Waeber B, Nussberger J: Angiotensin-converting
enzyme inhibitors. In: Messerli F,
ed. Cardiovascular Drug Therapy. 2nd ed. Philadelphia:
WB Saunders, 690–711, 1996.
3. Sica DA. Renin-angiotensin system blockade:
Therapeutic Agents. In: Singh AJ, William GH
(Eds). Textbook of Nephro-Endocrinology. (1st edition),
New York, New York. Elsevier 189, 2009.
4. Ahimastos AA, Lawler A, Reid CM, et al: Ramipril
markedly improves walking ability in patients with
peripheral arterial disease. Ann Intern Med 144:
660, 2006.
5. Cheng A, Frishman WH: Use of angiotensin-converting
enzyme inhibitors as monotherapy and in
combination with diuretics and calcium channel
blockers. J Clin Pharmacol 38:477, 1998.
6 Yusuf S, Sleight P, Pogue J, et al: Effects of an angiotensin-converting
enzyme inhibitor, ramipril,
on cardiovascular events in high-risk patients. The
Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med 342:145, 2000.
7. Fox KM, EURopean trial On reduction of cardiac
events with perindopril in stable coronary artery
disease investigators. Efficacy of perindopril in reduction
of cardiovascular events among patients
with stable coronary artery disease: randomized,
double-blond, placebo-controlled, multicentre trial
(the EUROPA study). Lancet 362: 782, 2003.
8 Giatras I, Lau J, Levey SS: Effect of angiotensinconverting
enzyme inhibitors on the progression
of nondiabetic renal disease: A meta-analysis of
randomized trials. Ann Intern Med 127:337, 1997.
9. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting
enzyme inhibitors and progression
of nondiabetic renal disease. A meta-analysis of
patient-level data. Ann Intern Med 135:73, 2001.
10. Hoogwerf BJ. Renin-angiotensin system blockade
and cardiovascular and renal protection. Am J Cardiol
105 (1 Suppl):30A, 2010.
11. Garg R, Yusuf S, for the Collaborative Group on
ACE Inhibitor Trials. Overview of randomized trials
of angiotensin-converting enzyme inhibitors on
mortality and morbidity in patients with heart failure.
JAMA 273:1450, 1995.
12. Law MR, Morris JK, Wald NJ. Use of blood pressure
lowering drugs in the prevention of cardiovascular
disease: meta-analysis of 147 randomised trials in
the context of expectations from prospective epidemiological
studies. BMJ 338: B1665, 2009.
13. Kjeldsen SE, Julius S. Hypertension mega-trials
with cardiovascular end points: effect of angiotensin-converting
enzyme inhibitors and angiotensin
receptor blockers. Am Heart J 148. 747, 2004.
14. Toto R: Angiotensin II subtype 1-receptor blockers
and renal function. Arch Intern Med 161:1492,
2001.
15. Al Khalaf MM, Thalib L, Doi SA. Cardiovascular
outcomes in high-risk patients without heart failure
treated with ARBs: a systematic review and
meta-analysis. Am J Cardiovasc Drugs 9:29, 2009.
16. JAMAli AH, Tang WH, Khot UN, Fowler MB: The
role of angiotensin receptor blockers in the management
of chronic heart failure. Arch Intern Med
161:667, 2001.
17. Johnston C, Risvanis J: Preclinical pharmacology
of angiotensin II receptor antagonists: Update and
outstanding issues. Am J Hypertens 10:306S, 1997.
18. Burnier M: Angiotensin II type 1-receptor block-
Cardiovascular Pharmacotherapeutics, 3rd ed, Abridged and Updated. © 2012 William H. Frishman and Domenic A. Sica, eds. Cardiotext
Publishing, ISBN: 978-1-935395-52-2.
9-1